Navigation Links
NexGenix Pharmaceuticals to Present at Two Industry Conferences: Rodman & Renshaw 11th Annual Healthcare Conference and Life Sciences Summit 2009
Date:9/10/2009

NEW YORK, Sept. 10 /PRNewswire/ -- NexGenix Pharmaceuticals Holdings, Inc. (Privately Held) today announced that Chief Executive Officer Dr. Allan E. Rubenstein will be presenting at two industry conferences during the month of September. The first presentation will take place on September 11th, 2009 at 11:40am as part of the Rodman & Renshaw 11th Annual Healthcare Conference in New York, New York. The second presentation will take place on September 23, 2009 at 4:15pm as part of the Life Sciences Summit 2009 in Hauppauge, New York. All times are local time.

Dr. Rubenstein will be presenting an overview of the Company's preclinical results related to its series of heat shock protein 90 (Hsp90) inhibitors, speak about the Company's forward drug development strategy and timeline, and present high-level fiscal results for 2009.

About NexGenix: NexGenix Pharmaceuticals Holdings, Inc. is a privately-held biotechnology company based in New York City. The Company's portfolio consists of a series of Hsp90 inhibitors, a novel target therapy for oncology and neurodegenerative disorders, which has attracted an enormous amount of development interest in the past several years. The Company's proprietary Hsp90 screening platform has already generated over 300 potential compounds. From this group, three lead drug candidates have been identified on the basis of superior efficacy, safety, and the ability to cross the blood brain barrier. The product profiles lend themselves to address diseases such as glioblastoma (or "glioma", commonly known as malignant brain tumor) and other cancers, as well as neurodegenerative disorders including the motor neuron disease ALS (Lou Gehrig's disease) and Parkinson's disease. Each of these indications represents a world-wide market of at least $1B/year. In addition, the Company has a clinical stage intralesional treatment for dermal neurofibromas, the most co
'/>"/>

SOURCE NexGenix Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the Annual Meeting of the American Association for Cancer Research (AACR); Scientific Advisory Board Chairman Tyler Jacks Named President-elect
2. NexGenix Pharmaceuticals Enters into Exclusive World-wide License to Develop Novel Hsp90 Inhibitors
3. ISTA Pharmaceuticals to Present at NewsMakers in the Biotech Industry Conference
4. Access Pharmaceuticals Provides Update on ProLindac(TM)Clinical Development Plan
5. Mpex Pharmaceuticals Announces Positive Phase 2b Clinical Trial Results with Aeroquin(R) (MP-376) Treatment in Cystic Fibrosis Patients
6. Esperance Pharmaceuticals Announces Initiation of Clinical Studies of its Novel Membrane-disrupting Agent, EP-100, in Patients with Cancer
7. Rib-X Pharmaceuticals to Present at the 49th ICAAC
8. Cadence Pharmaceuticals to Present at Two Investment Conferences During the Month of September 2009
9. Dont Wait to Innovate: Future Pharmaceuticals Magazine Releases Its Issue on Innovation in IT, Cell-Based Therapy and Supply Chains
10. EnVivo Pharmaceuticals Names Stephen DiPalma Chief Financial Officer
11. Oramed Pharmaceuticals Commences Human Clinical Trials of an Oral GLP-1 Analog
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... RURO Inc. is pleased to announce ... refinement to the smart management solution. , ezColony, ... methodical management for transgenic animal colonies, genotyping and ... platform provides user access with a plethora of ... emphasize streamlined tasks, such as animal relocation to ...
(Date:5/16/2013)... 2013 The Stirling Ultracold Model ... Inc., Athens, OH, USA, won the Outstanding New Product ... Society for Biological and Environmental Repositories (ISBER) at their ... one product annually, recognizes the company’s development and introduction ... The award was presented to Global Cooling’s CEO ...
(Date:5/16/2013)... 2013 A new selection of ... Cole-Parmer is designed to meet the dynamic needs ... The new Cole-Parmer® MS-3400 Centrifuges are ... lab. They ensure a powerful and complete separation ... Their standard four-place swinging buckets hold 50-mL tubes. ...
(Date:5/16/2013)... , May 16, 2013  The registration deadline has ... Financial Officers (ABFO) 2013 National Conference, the premier conference ... May 28-31 at the Hilton San Diego Bayfront. ... this year,s conference and want to make sure as ... said Brandi Roberts , Chief Financial ...
Breaking Biology Technology:RURO Introduces ezColony 4.1 – The Versatile Transgenic Animal Colony Management Software 2Stirling Ultracold Ultra-Low Freezer Wins 2013 Outstanding New Product Award at International Biorepository Conference, Sydney, Australia 2Cole-Parmer Offers Enhanced Selection of Centrifuges 2Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego 2Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego 3Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego 4
... , SEATTLE, Nov. 11 Dendreon Corporation (Nasdaq: DNDN ... 2009. Revenue for the third quarter of 2009 was $25,000 ... Revenue for the nine months ended September 30, 2009 was ... 30, 2008. , Dendreon,s total operating expenses for the ...
... MADRID, November 11 Cellerix, a ... today announced the successful first closing of its financing ... current,shareholders and a select group of new investors. Cellerix ... , This round was led ...
... AMSTERDAM, November 11 Amsterdam ... human gene therapy,announced today that it has successfully treated ... proprietary gene therapy. The proof of,concept studies were performed ... of Rome, La Sapienza, Italy) and demonstrated,effectiveness in the ...
Cached Biology Technology:Dendreon Reports Third Quarter 2009 Financial Results and Continuing Progress Toward PROVENGE Commercialization 2Dendreon Reports Third Quarter 2009 Financial Results and Continuing Progress Toward PROVENGE Commercialization 3Dendreon Reports Third Quarter 2009 Financial Results and Continuing Progress Toward PROVENGE Commercialization 4Dendreon Reports Third Quarter 2009 Financial Results and Continuing Progress Toward PROVENGE Commercialization 5Dendreon Reports Third Quarter 2009 Financial Results and Continuing Progress Toward PROVENGE Commercialization 6Cellerix Raises EUR27 Million in a First Closing 2AMT Successful in Preclinical Treatment of DMD 2AMT Successful in Preclinical Treatment of DMD 3
(Date:5/18/2013)... (May 18, 2013) Research presented at Digestive ... digestive health through diet and lifestyle. , ... by reduced muscle strength, fatigue and poor quality ... patients are in remission. A randomized, double blind, ... vitamin D supplementation corresponded to significant relief of ...
(Date:5/17/2013)... AGA Research Foundation announced a new grant that intends ... microbiota, one of today,s most exciting areas of science, ... Research Awards Panel selected Andrew T. Chan, MD, MPH ... Medical School, Boston, as the 2013 AGA-Elsevier Gut Microbiome ... of funding, commencing in July 2013, to test the ...
(Date:5/17/2013)... Jersey, and City University of New York have invented ... effectively clears organisms to be viewed under microscopes. Visikol ... is one of the few high-quality clearing solutions currently ... Enforcement Administration (DEA) due to its use as a ... for viewing organisms under a microscope. Without them, microscope ...
Breaking Biology News(10 mins):Research examines new methods for managing digestive health 2Research examines new methods for managing digestive health 3New gut microbiome research to explore red meat -- colorectal cancer pathway 2New formula invented for microscope viewing, substitutes for federally controlled drug 2New formula invented for microscope viewing, substitutes for federally controlled drug 3
... calculated that the bite force of the great white,s ... (also known as Big Tooth) is the highest ... carnivore ever to have existed. Shark researchers from ... Department of Primary Industries Fisheries (Australia) and University of ...
... Fruit and Vegetable Consumption Is Low among Black Men ... fruits and vegetables, daily consumption of these foods among ... researchers at Columbia and Temple universities, the University of ... study of 490 American and foreign-born black men between ...
... - JDRF said today that it has recognized the work ... the pace of science in understanding the autoimmune attack that ... severe complications of this chronic and life-threatening disease. ... Dr. Jeffrey A. Bluestone, Director of the Diabetes Center at ...
Cached Biology News:Great white's mighty bite revealed 2Highlights from the August 2008 Journal of the American Dietetic Association 2JDRF announces 2008 Scholar Award recipients 2JDRF announces 2008 Scholar Award recipients 3
Rabbit polyclonal to ZFP200 ( Abpromise for all tested applications). Antigen: Synthetic peptide: CGKSFNHKTNLNKHER (Human) Entrez Gene ID: 7752 Swiss Protein ID: P98182...
Human Ig Lambda-chain, clone ICO-16, Monoclonal Antibody...
Rabbit polyclonal to Warfarin ( Abpromise for all tested applications). Antigen: Chemical / Small Molecule conjugated to KLH...
WNV Core Antibody...
Biology Products: